DIRS.INFO The most relevant business & tech news

☆ Wells Fargo becomes bullish on this biotech company
▼ + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.

Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ Stocks making the biggest moves after hours: Box, MongoDB, Dave & Buster's and more
▼ + stars: | 2023-12-05 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Box — The cloud company plummeted 11% after reporting fiscal third-quarter adjusted earnings of 36 cents per share on revenue of $261.5 million. This was lower than FactSet's analyst expectations of 38 cents per share on $262.4 million of revenue. MongoDB — The database stock shed 4% despite MongoDB beating analysts' expectations in its third-quarter earnings. The company's $167 million revenue was also above the forecast $164 million. Dave & Buster's — The stock slipped 3% after the company posted third-quarter revenue of $466.9 million, lower than analysts' forecast for $473 million, per LSEG.

Persons: Asana, Buster's, LSEG Organizations: LSEG, Biosciences, U.S . Food, Drug Administration, crinecerfont, Toll Locations: U.S

☆ These tenbagger stocks are well liked by analysts and may rally even more
▼ + stars: | 2023-12-03 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Over the last 10 years of market turbulence, there haven't been very many stocks that have seen a more than 1,000% compound return. Fewer still of these "tenbaggers," companies that have multiplied in value 10 times, have sizeable upside expectations ahead. The average analyst still sees potential upside of 40%. Early last month, Jefferies began research coverage of Celsius with a buy rating, citing several growth opportunities that lie ahead. With a 10-year compound total return of nearly 13,000%, chipmaker Nvidia was also at the top of the list.

Persons: Jefferies, Kaumil Gajrawala, Fred Imbert Organizations: CNBC, Holdings, PepsiCo, Nvidia, Microsoft, Semiconductor, Broadcom, Builders, Neurocrine Biosciences Locations: Florida

Search resuls for: "Neurocrine Biosciences"

4 mentions found